C5-anilinoquinazoline compounds and their use in treating cancer
申请人:AstraZeneca AB
公开号:US10273227B2
公开(公告)日:2019-04-30
The invention concerns compounds of Formula (I):
or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
C5-anilinoquinazoline Compounds and Their Use in Treating Cancer
申请人:AstraZeneca AB
公开号:US20190263787A1
公开(公告)日:2019-08-29
The invention concerns compounds of Formula (I):
or pharmaceutically acceptable salts thereof, wherein R
1
, R
2
, R
3
and R
4
have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
[EN] C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER<br/>[FR] COMPOSÉS DE C5-ANILINOQUINAZOLINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
申请人:ASTRAZENECA AB
公开号:WO2018197642A1
公开(公告)日:2018-11-01
The invention concerns compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER
申请人:AstraZeneca AB
公开号:US20180312490A1
公开(公告)日:2018-11-01
The invention concerns compounds of Formula (I):
or pharmaceutically acceptable salts thereof, wherein R
1
, R
2
, R
3
and R
4
have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.